Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...
QOL Medical to Acquire All Outstanding Shares of Evoke for $11.00 Per Share in Cash Represents a 139.7% premium to most recent Nasdaq closing price Transaction expected to close by the end of 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback